RU2018133026A - COMBINATION OF ANTIALLERGIC AGENT WITH MUSCARINE RECEPTOR ANTAGONIST AND / OR DOPAMINERGIC RECEPTOR ANGONIST FOR APPLICATION FOR PREVENTION / STOPPING OF PROCESS OF AXIOPE Axiale - Google Patents
COMBINATION OF ANTIALLERGIC AGENT WITH MUSCARINE RECEPTOR ANTAGONIST AND / OR DOPAMINERGIC RECEPTOR ANGONIST FOR APPLICATION FOR PREVENTION / STOPPING OF PROCESS OF AXIOPE Axiale Download PDFInfo
- Publication number
- RU2018133026A RU2018133026A RU2018133026A RU2018133026A RU2018133026A RU 2018133026 A RU2018133026 A RU 2018133026A RU 2018133026 A RU2018133026 A RU 2018133026A RU 2018133026 A RU2018133026 A RU 2018133026A RU 2018133026 A RU2018133026 A RU 2018133026A
- Authority
- RU
- Russia
- Prior art keywords
- component
- pharmaceutical active
- anticholinergic
- antihistamine
- combination
- Prior art date
Links
- 230000003291 dopaminomimetic effect Effects 0.000 title claims 5
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 title 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 title 1
- 239000000043 antiallergic agent Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 6
- 230000001078 anti-cholinergic effect Effects 0.000 claims 6
- 239000000739 antihistaminic agent Substances 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 4
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 claims 3
- 230000001387 anti-histamine Effects 0.000 claims 3
- 230000003326 anti-histaminergic effect Effects 0.000 claims 3
- 229960002028 atropine sulfate Drugs 0.000 claims 3
- 229940126403 monoamine reuptake inhibitor Drugs 0.000 claims 3
- 235000004347 Perilla Nutrition 0.000 claims 2
- 241000229722 Perilla <angiosperm> Species 0.000 claims 2
- 230000004329 axial myopia Effects 0.000 claims 2
- CPFJLLXFNPCTDW-BWSPSPBFSA-N benzatropine mesylate Chemical compound CS([O-])(=O)=O.O([C@H]1C[C@H]2CC[C@@H](C1)[NH+]2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 CPFJLLXFNPCTDW-BWSPSPBFSA-N 0.000 claims 2
- 229940024774 benztropine mesylate Drugs 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- 229960003638 dopamine Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 claims 2
- 229960003630 ketotifen fumarate Drugs 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- 229930003347 Atropine Natural products 0.000 claims 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 1
- 239000000939 antiparkinson agent Substances 0.000 claims 1
- 229960000396 atropine Drugs 0.000 claims 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims 1
- 229960000686 benzalkonium chloride Drugs 0.000 claims 1
- 229960001081 benzatropine Drugs 0.000 claims 1
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 claims 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical group [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 claims 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 1
- 239000003349 gelling agent Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 claims 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims 1
- 235000019799 monosodium phosphate Nutrition 0.000 claims 1
- -1 or anticholinergic Chemical compound 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Claims (10)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102016000017487 | 2016-02-19 | ||
| ITUB2016A000876A ITUB20160876A1 (en) | 2016-02-19 | 2016-02-19 | COMBINATION OF AN ANTIALLERGIC AGENT WITH A MUSCARIN ANTAGONIST AND / OR A DOPAMINERGIC AGONIST FOR THE USE IN PREVENTION / ARREST OF MIOPIA IN THE MAN |
| PCT/EP2017/053619 WO2017140846A1 (en) | 2016-02-19 | 2017-02-17 | Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018133026A true RU2018133026A (en) | 2020-03-19 |
| RU2018133026A3 RU2018133026A3 (en) | 2020-04-24 |
| RU2793238C2 RU2793238C2 (en) | 2023-03-30 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| IL260893B1 (en) | 2023-04-01 |
| SG11201806599SA (en) | 2018-09-27 |
| ITUB20160876A1 (en) | 2017-08-19 |
| EP3416617C0 (en) | 2024-12-18 |
| BR112018016845A2 (en) | 2018-12-26 |
| IL260893B2 (en) | 2023-08-01 |
| AU2017220640B2 (en) | 2022-08-25 |
| ES3009760T3 (en) | 2025-03-31 |
| EP3416617A1 (en) | 2018-12-26 |
| KR20180117642A (en) | 2018-10-29 |
| CN108883060A (en) | 2018-11-23 |
| EP3416617B1 (en) | 2024-12-18 |
| IL260893A (en) | 2018-09-20 |
| WO2017140846A1 (en) | 2017-08-24 |
| US20230172904A1 (en) | 2023-06-08 |
| JP2019505542A (en) | 2019-02-28 |
| RU2018133026A3 (en) | 2020-04-24 |
| CA3013846A1 (en) | 2017-08-24 |
| US20200253951A1 (en) | 2020-08-13 |
| SG10202007417SA (en) | 2020-09-29 |
| PL3416617T3 (en) | 2025-06-02 |
| AU2017220640A1 (en) | 2018-10-04 |
| HRP20250270T1 (en) | 2025-04-25 |
| CL2018002196A1 (en) | 2019-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY204185A (en) | Composition and methods for the treatment of myopia | |
| BR112018015273A2 (en) | benzimidazole derivatives as ror-gamma modulators | |
| BR112017007460A2 (en) | ror-gamma dihydropyrrolopyridine inhibitors | |
| MX2019007587A (en) | OPHTHALMIC COMPOSITION FOR THE TREATMENT OF DRY EYE DISEASE. | |
| JP2017531033A5 (en) | ||
| MX2017003215A (en) | Cenicriviroc combination therapy for the treatment of fibrosis. | |
| BR112022010891A2 (en) | COMBINATION OF AN AZETIDINE LPA1 RECEPTOR ANTAGONIST WITH ANTIFIBROTIC AGENTS | |
| AR054371A1 (en) | METHODS AND COMPOSITIONS FOR HANDLING PSYCHOTIC DISORDERS | |
| BR112018005904A2 (en) | compound, and method of preventing and / or treating hiv. | |
| PH12017501424B1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| RS52941B (en) | Combination of alpha 7 nicotinic agonists and antipsychotics | |
| BR112018005870A2 (en) | compound, and method of preventing and / or treating hiv. | |
| MX2024000828A (en) | ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR THE TREATMENT OF BLEPHARITIS. | |
| MA42016A1 (en) | Pharmaceutical compositions containing an integrin alpha 4 antagonist, used for the treatment of ocular inflammatory conditions | |
| HRP20250270T1 (en) | Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human | |
| MX379497B (en) | Use of prostacyclin antagonists for treating ocular surface nociception | |
| PH12019502510A1 (en) | Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof | |
| EA201892529A1 (en) | COMBINATION OF PURE ANTAGONISTS OF 5-HTRECEPTORS WITH ACETYLHOLINESTERASE INHIBITORS | |
| WO2018234871A3 (en) | Compositions for drug delivery and methods of use thereof | |
| BR112018073410A2 (en) | antagonist combination, use of the combination, method of treatment, compound, method for the treatment of alzheimer's disease and pharmaceutical composition | |
| BR112018073396A2 (en) | antagonist combination, use of a combination, method for treating cognitive disorders, compound, method for treating alzheimer's disease and pharmaceutical composition | |
| BR112018003181A2 (en) | compound, composition, and method for treating HIV infection | |
| HK1252549A1 (en) | Controlled-release tozadenant formulations | |
| WO2020065090A3 (en) | 5-ht7 antagonist for the treatment of dementia-associated tauopathies | |
| EA202090965A1 (en) | WATER COMPOSITIONS BILASTIN |